Roger Li: The final results of the CORE001 trial are out now in Nature Medicine
Patrick Hwu shared a post by Roger Li, Urologic oncologist at Moffitt Cancer Center, on X, adding:
“Roger Li shares results of the phase 2 CORE-001 trial, published in Nature Medicine.
The innovative combination therapy shows promise for Bladder Cancer patients who were unresponsive to standard treatment.”
Quoting Roger Li’s post:
The final results of the CORE001 trial are out now in Nature Medicine.
35 patients with BCG-UR CIS treated with Creto + pembro:
- 12mo CR (per RBB) = 57.1% (ITT)
- 24mo CR = 54% *(Auth Corr)
- No patient progressed to MIBC
- No synergistic toxicity.”
Read further
Source: Patrick Hwu/X and Roger Li/X
Dr. Patrick Hwu, MD, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T-cell therapy. He notably contributed seminal work on the development of the first chimeric antigen receptor aimed at combating cancer. His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance.